Rather, a discount in revenues because of lower drug prices may reduce case study answer astronomical acquisition prices now being paid by case study solution large manufacturers to purchase ideas made by others. But case study answer biopharmaceutical atmosphere will proceed to thrive as long as people who definitely innovate are provided with case study solution components to take action while those who play other roles in bringing new drugs to market are fairly compensated for their contributions to those elements of case study solution development procedure. As a contemporary report from case study solution National Academies of Medicine concluded, drugs that aren’t cost effective are of little value and drugs that do not exist are of no value. case study answer challenge of affordability are not solved if Congress keeps to succumb to questionable assertions by lobbyists claiming that excessively high drug prices are a must have to keeping up biopharmaceutical innovation. Passage of legislation to curb ridiculously high medicine prices and value raises will not only make drugs more available to sufferers but will also reduce government charges on drugs by greater than $345 billion dollars over 10 years, based on case study solution Congressional Budget Office. That will enable case study solution authorities to make greater investments in NIH and produce a fair more robust biomedical innovation surroundings than now exists.